Evidence mapPaperPMID 37765126Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question.

Vera Tocci, Maria Mirabelli, Alessandro Salatino, Luciana Sicilia, Stefania Giuliano, Francesco S Brunetti, Eusebio Chiefari, Giovambattista De Sarro, Daniela P Foti, Antonio Brunetti

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. The Double-Edged Sword of Gestational Insulin Resistance: Navigating Maternal Adaptation and Its Risks for Pregnancy and Offspring Health.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  3. Article
  4. Effect of Initial Glucose Tolerance Test Response on Pregnancy Outcomes in Type A1 Gestational Diabetes.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Vera TocciDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-9241-1848
Maria MirabelliDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-6427-7186
Alessandro SalatinoDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-9241-0768
Luciana SiciliaOperative Unit of Endocrinology, Diabetes in Pregnancy Ambulatory Care Center, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy.
Stefania GiulianoOperative Unit of Endocrinology, Diabetes in Pregnancy Ambulatory Care Center, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy.
Francesco S BrunettiDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Eusebio ChiefariDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Giovambattista De SarroDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-7629-6579
Daniela P FotiDepartment of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0002-9536-5736
Antonio BrunettiDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0003-1533-8779
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been a dramatic increase in the number of pregnancies complicated by gestational diabetes mellitus (GDM). GDM occurs when maternal insulin resistance develops and/or progresses during gestation, and it is not compensated by a rise in maternal insulin secretion. If not properly managed, this condition can cause serious short-term and long-term problems for both mother and child. Lifestyle changes are the first line of treatment for GDM, but if ineffective, insulin injections are the recommended pharmacological treatment choice. Some guidance authorities and scientific societies have proposed the use of metformin as an alternative pharmacological option for treating GDM, but there is not yet a unanimous consensus on this. Although the use of metformin appears to be safe for the mother, concerns remain about its long-term metabolic effects on the child that is exposed in utero to the drug, given that metformin, contrary to insulin, crosses the placenta. This review article describes the existing lines of evidence about the use of metformin in pregnancies complicated by GDM, in order to clarify its potential benefits and limits, and to help clinicians make decisions about who could benefit most from this drug treatment.

Indexed as

fetal developmentgestational diabetes mellitusguidelinesmetformintransgenerational effects

Identifiers

PMID37765126
PMCPMC10537239
OpenAlexW4386863988

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.